Genzyme commits $100m upfront for Voyager's gene therapy expertise in CNS

Sanofi company Genzyme has entered a collaboration with Cambridge, Massachusetts-based Voyager Therapeutics focused on the discovery of gene therapies for severe CNS disorders.

Sanofi company Genzyme has entered a collaboration with Cambridge, Massachusetts-based Voyager Therapeutics focused on the discovery of gene therapies for severe CNS disorders.

Voyager was launched in 2014 with $45m in Series A venture capital financing from Third Rock Ventures.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category